Selective ARF6 inhibitor (IC50
= 1.0 μ
M). Selective for ARF6 over other ARF family members and small GTPases. Inhibits ARF6 activation in uveal melanoma cells in vitro
and blocks downstream signaling pathways of oncogenic GNAQ. Reduces tumorigenesis in mouse model of uveal melanoma.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma.
Yoo et al.
Cancer Cell., 2016;29:889